Strategic funding Phase 2 clinical candidate with FDA Fast Track designation and NIH SBIR funding validates the technology and signals potential for accelerated regulatory pathways and favorable funding conversations with government and impact-focused investors.

Sustainability edge Gadolinium-free manganese-based MRI contrast offers a safer, environmentally friendlier alternative, addressing safety and regulatory concerns that influence hospital procurement and payer considerations.

Clinical momentum Current clinical stage and SBIR-backed recognition present a compelling story for early-engagement discussions with large imaging providers, academic medical centers, and contract research organizations seeking innovative imaging solutions.

Market need Large addressable market of over 60 million contrast-enhanced MRI scans annually, with supply-chain resilience emphasis, creates opportunities to partner with major imaging manufacturers and distributors aiming to diversify contrast portfolios.

Funding readiness Recent fast-track designation and ongoing government grants position Reveal for compelling ROI conversations with strategic investors and potential co-development or licensing partners seeking differentiated, scalable imaging agents.